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Chapter 6
How Far Are We from Dose On Demand
of Short-Lived Radiopharmaceuticals?
Giancarlo Pascali and Lidia Matesic
Abstract PET radiopharmaceuticals are currently produced using a centralized
approach, which makes sustainable the distribution to few imaging centers of an
only small set of tracers (virtually only [18F]FDG). However, a wider set of
structures have demonstrated a potential applicability for imaging in a specific
manner several disease condition. In order to allow this wider and more personal-
ized use of PET imaging, the production paradigms need to be changed. In this
contribution we will explain how Dose-On-Demand systems can be conceptualized
and what are the challenges that are still to be overcome in order for such approach
to be of widespread utility.
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6.1 Introduction
The clinical production of radiopharmaceuticals or radiotracers for positron-
emitting tomography (PET) is currently performed in centralized locations such
as commercial radiopharmacies or some dedicated radiochemistry facilities. Gen-
erally, these facilities contain a cyclotron to produce the PET radioisotope and
laboratories furnished with lead-shielded hot cells containing automated
radiosynthesis modules to produce the radiotracer. Quality control equipment is
also required to validate and confirm the purity of the radiotracer prior to its
dispatch to the imaging centers.
The majority of radiotracer production facilities synthesize [18F]FDG, the gold
standard for detecting a variety of cancers. Nowadays, [18F]FDG can be produced
in a large batch, making it relatively affordable. Portions can then be dispatched and
transported by road or air to the relevant hospital owing to the half-life of fluorine-
18 (110 min).
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A major challenge in clinical PET radiochemistry is that there are a greater
number of hospitals or PET clinics than there are PET radiotracer production
facilities. Furthermore, the demand for new clinical PET radiotracers is low due
to the cost of production in a centralized location. New PET radiotracers are
overwhelmingly used for research purposes only.
To overcome this obstacle, a decentralized approach has been envisaged
[1]. Here, scientists could produce their radiotracer of interest in-house, economi-
cally and on demand, leading to a concept that we have defined as Dose On Demand
(DOD). This short review will cover the important aspects of DOD and detail the
journey toward the DOD of short-lived radiopharmaceuticals.
6.2 DOD Features
The current production approach of PET radiotracers imposes several limitations
and challenges for guaranteeing the most efficient organization of imaging studies
[2]. A possible way to improve this situation would require a system for which the
type and the quantity of the produced tracer is defined and directly handled by an as
final as possible user (e.g., hospital pharmacy, imaging laboratory). This system
should implement the reduction to the minimum possible of the amounts of
radioactivity and chemicals needed in the preparation, added to an overall simpli-
fication of the production process. Such conceptual process can be defined as “Dose
On Demand” (DOD) [3, 4, 5]: the operation of producing a radiopharmaceutical
in the shortest time possible, using the minimum amount of chemicals and radio-
activity strictly needed for the production of the single (or few) imaging dose
(s) required.
This approach, exemplified in Fig. 6.1, would provide several benefits to the
overall PET community. Firstly, it will hand over flexibility in the application
directly to the hospital/imaging center, which can decide on a patient basis which
tracer to produce and when; this could also happen in small regional centers, thus
not forcing anymore interested patients to commute long distances to the few useful
imaging hospitals. This flexibility will also allow the utilization of rare or research
tracers to be facilitated, as in this system the small amounts of chemicals and
radioactivity needed for a DOD production would be economically sustainable
for a single imaging center. Secondly, while a fault in production from a centralized
approach will have impact on a large number of patients, a fault in one DOD system
will have an impact limited to the patients utilizing those doses only. Lastly, due to
the reduction in raw materials needed (as well as related topics, e.g., safety, storage)
and the redistribution of running costs over more institutes, the imaging doses will
result in a reduced cost and in tracers’ availability to a wider population.
In order to realize a DOD process, few requirements can be envisaged.
Firstly, the production needs to be implemented on an automated instrument that
can implement preset operations, as well as allowing remote interaction of the
operator for minor modifications (i.e., “Automation”). In addition, it has to have
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real-time monitoring and audit trail capabilities for monitoring and trending pur-
poses. Secondly, the instrument used needs to be able to handle small aliquots of
reagents, from fractions to hundreds of μL (i.e., “Discretization”) with accuracy and
repeatability. The handling operations comprise moving, merging, mixing, heating,
and similar processes. In other words, the instrument has to be capable to give a
defined “chemical history” to any given aliquot of reagents used (that can be
different among several aliquots). Thirdly, the processes implemented need to be
serially repeatable with minimum operator intervention (“Restarting”). This can be
achieved by substituting single-use parts in the system or by cleaning it using
validated procedures. A final peculiarity that contributes to achieving DOD is the
need to use the minimum amount of chemicals (“Reduction”), which would max-
imize the atom efficiency of the process, as well as allow an acceptable sacrifice in
employing single-use parts or realize a faster cleaning of the system.
If all these requirements can be respected in a process system, a DOD production
can be implemented and can be used to produce several doses of the same tracer or
of different tracers, using the same system and minimal operator interventions.
6.3 Early Examples Conducible to DOD
The possibility to tailor the production of nuclear medicine (NM) tracers as much as
possible to the needs of the final user has always been present, and indeed some
example of approaches that can be linked to DOD concept can be found in early and
current practices.
Fig. 6.1 Comparison between traditional centralized approach and DOD
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Generators of radioactive raw nuclides have been widely used (e.g., 99mTc,
68Ga) [6]; the elution of the desired radionuclide is generally done upon demand
and followed by simple chemical reactions (generally performed directly in the
same NM department) to obtain the final radiopharmaceutical. This approach
respects the Restarting requirement, though limited to the raw nuclide production
and not to the pharmaceutical preparation; however, it generally does not respect
the Discretization nor the Reduction requirements, as it is difficult to separately
handle the amount of chemicals needed for a single patient (i.e., in the μLs range). It
sometimes respects the Automation requirement, but in most NM departments,
these preparations are performed manually.
The use of very short half-life nuclides can be natively defined as a DOD
application, as their handling must be done shortly before their use in imaging.
Typical examples are the production of [15O]-H2O [7] and [
13N]-NH3 [8]; shortly
after production, the systems utilized can be restarted easily due to their simple
setup and the fast decay of process wastes. However, also in this case, these
processes cannot be properly defined as DOD since they generally respect the
Automation and the Restarting requirements, but neither the Discretization nor
the Reduction (i.e., no difference if the production is used for one or several
contemporary patients). 11C chemistry [8] also falls within the use of very short
half-life nuclides as more productions can be run on the same machine on the same
day. However, also in this case, the typical systems used can be even less defined as
DOD, due to its relatively longer half-life (compared to 15O and 13N).
Currently, the approach that most resembles DOD is represented by the cassette-
based systems. In this case, Automation and Restarting requirements can be easily
achieved; Discretization and Reduction are generally not pursued, because nowa-
days these systems are used for single-batch productions, but the principles under-
lying cassette philosophy could be used to project single-use/single-dose cassettes.
In fact, these systems are basically very compact macrofluidic systems; this under-
standing clarifies how microfluidic concepts can be the ones that should allow a full
implementation of DOD in radiopharmaceutical production.
6.4 DOD Proof-of-Principle Examples
6.4.1 Minicyclotron/Minichemistry/MiniQC
The Biomarker Generator (BG75), made by ABT Molecular Imaging, is a small
(0.37 m 1.25 m) self-shielded 7.5 MeV cyclotron coupled to an aseptic single-use
card-based automated chemical production module and an automated module for
quality control. The BG75 was initially used for the DOD production of [18F]
fluoride and [18F]FDG [9]. Using the computer’s software, the operator is able to
select whether the [18F]fluoride or [18F]FDG is to be produced. For the production
of [18F]fluoride (~1 mCi/min at 5 μA), the process is complete once the product is
delivered into the specified vial. Alternatively, for the production of [18F]FDG, the
82 G. Pascali and L. Matesic
software prompts the operator to prepare the tracer-specific Dose Synthesis Card
(DSC) and the chemistry and quality control modules while the cyclotron is
preparing the [18F]fluoride. The radiosynthesis is then completed on the DSC,
including relevant purification, and dispensed into a shielded, sterile syringe or
vial. An aliquot of the product is removed for quality control (pH determination,
acetonitrile and ethanol residual solvent determination, radiochemical identity and
purity, Kryptofix 2.2.2. determination, and a filter integrity test), which is automat-
ically performed by the system, without any operator input.
The BG75 has been able to consistently produce a 10–13 mCi dose of [18F]FDG
at 40 min intervals up to six times per day, with products meeting the required USP
limits for release [9]. To date, other DOD radiotracers synthesized using the BG75
include Na[18F]F [10] and [18F]FMISO [11, 12].
6.4.2 Continuous Flow Microfluidics
Interestingly, proof-of-concept studies have been recently conducted into the pro-
duction of [18F]FLT using the cyclotron component of the BG75 system and the
Advion NanoTek microfluidic system [13]. Between 70 and 80 mCi of [18F]fluoride
were produced by the minicyclotron and the radiosynthesis was subsequently
performed under continuous-flow microfluidic conditions to yield [18F]FLT in
sufficient quantity and purity for clinical trials. The number of radiochemists
using a microfluidic approach has been steadily accumulating in recent years.
This may be related to the advantages of microfluidic systems over traditional
automated radiochemistry modules, which include a decrease in the amount chem-
ical reagents used, shorter reaction times, greater radiochemical yields, the ability
to use solvents under supercritical conditions, and reduced radiation exposure to the
operator due to the lower amounts of radioactivity used. The NanoTek Microfluidic
Synthesis System by Advion was the first commercially available continuous-flow
microfluidic system. The system comprises a concentrator module to azeotropically
evaporate the [18F]fluoride from the cyclotron and subsequently reconstitute the
isotope into the appropriate solvent; a pump module containing two syringe pumps
and loops to store chemical precursors and a reactor module, which contains a
syringe pump and loop to house the isotope along with thermostatted slots to store
up to four microreactors, where the radiochemical reactions occur.
The previous example of the production of [18F]FLT is the latest in a growing list
of radiotracers prepared using the NanoTek system. The first instance was the
production of [18F]fallypride for use in micro-PET studies [14]. Initially, the
radiochemical optimization of [18F]fallypride was conducted by dispensing 10 μL
solutions of the tosyl-fallypride precursor and [18F]fluoride complex into the
microreactor at 10 μL/min to obtain 1–1.5 mCi doses of [18F]fallypride. These
optimization reactions were performed sequentially and could be considered an
early form of DOD. Once the optimal radiochemical conditions were determined,
the authors were able to prepare a dose of [18F]fallypride sufficient for human
injection (15 mCi) by increasing the volume of the two solutions from 10 μL to
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200 μL. The authors also alluded to the fact that multiple high doses of [18F]
fallypride could be produced using the same microreactor. Soon after, Pascali
et al. [15] described the sequential radiolabeling of ethyl-ditosylate and propyl-
ditosylate in the NanoTek system using the same solution of [18F]fluoride complex
and swapping the precursor between productions by emptying and refilling the
precursor loop with a different substrate. These examples of DOD demonstrated the
economical use of the [18F]fluoride solution to yield two radiotracers on the same
day. The authors also sequentially prepared several injectable doses of [18F]CB102,
a cannabinoid type 2 receptor agonist, for small animal PET imaging, suggesting
that freshly prepared doses using a DOD approach were superior to a batch solution
to be used over a certain shelf life.
To further evaluate the robustness and reliability of a DOD approach, Pascali
et al. were able to produce three sequential doses of three different [18F]
fluorocholines with a total processing time of 13–15 min for each dose, including
SPE purification [5]. While this example includes a modification to the NanoTek
system to incorporate SPE purification, typically, the radiochemical outputs are
purified externally to the NanoTek system, particularly HPLC purification. Recent
examples include the preparation of [18F]FPEB [16], whereby the radiosynthesis
occurred in the NanoTek and the reaction output was sent to a vial preloaded with
water and pre-concentrated onto an Oasis HLB Light SPE cartridge to remove
DMSO present in the reaction mixture. The cartridge was eluted with acetonitrile
and water before being transferred to a GE TRACERlab FXFN synthesis unit to
conduct semi-preparative HPLC purification and formulation. Additionally, the
Tau imaging agent, [18F]T807, was produced with the same modifications
[17]. Three consecutive >100 mCi productions of [18F]T807 were performed for
validation purposes, and [18F]T807 became the first example of human use of a
radiopharmaceutical prepared by continuous-flow microfluidics.
The NanoTek system has been modified recently to include HPLC and SPE
purification [18]. By utilizing the cable harnessing of the system, a custom-made
electrical board was engineered whereby additional switches and analog signals
could be added and be controlled by the NanoTek software to activate externally
powered devices and record external signals (e.g., detectors), if applicable. This
customized system was able to produce 1- or 2-step radiotracers such as [18F]
CB102, [18F]fluoroethylcholine [18], [18F]MEL050 (melanin targeting) [19], [18F]
fallypride, and [18F]PBR111 (TSPO receptor) [20], in a DOD manner. Similarly,
[18F]FMISO has been produced by integrating a HPLC system to the NanoTek
through a six-port valve [21]. By fine-tuning the HPLC conditions for [18F]FMISO,
the authors were able to eliminate the requirement for SPE.
6.4.3 Peptide Labeling
While microfluidic systems have mainly been utilized to radiolabel small mole-
cules, reports of peptide or protein radiolabeling using microfluidics are limited.
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Early work in this area featured the direct [18F]radiolabeling of bombesin deriva-
tives (with 7–8 amino acid residues) that had been modified to incorporate trimethy-
lammonium or triarylsulfonium leaving groups [22]. The peptides could be
radiolabeled reproducibly, suggesting a possible DOD approach; however, due to
the harsh temperature conditions required for radiolabeling, this method would be
unsuitable for protein radiolabeling. An alternative route to radiolabel a peptide is
through the use of a prosthetic group as an indirect radiolabeling method. [18F]SFB
[23] and even, the most abundantly used PET tracer, [18F]FDG [24] have been
utilized as prosthetic groups for the radiolabeling of peptides. Although both
prosthetic groups were synthesized on macroscale equipment, the subsequent
peptide radiolabeling was performed under microfluidic conditions. In each case,
the peptide was radiolabeled in a shorter period of time, in higher radiochemical
yield (RCY), and using a smaller quantity of the peptide compared to conventional
radiolabeling techniques. Only recently has the first microfluidic radiosynthesis of a
prosthetic group and the ensuing peptide radiolabeling been reported [25]. Here, the
[18F]F-Py-TEP prosthetic group was prepared in the first microreactor of an Advion
NanoTek system from [18F]fluoride and the corresponding precursor. After exiting
the microreactor, the [18F]F-Py-TEP was transferred to a second microreactor,
where it reacted with a model peptide containing free amines. Once again, the
peptide coupling was faster than conventional methods and obtained in higher
RCY. These accounts all imply that the DOD of radiolabeled peptides for molecular
imaging is currently being explored and may be employed in the future.
6.4.4 Solid-Phase Approaches
Although the use of microfluidic conditions is leading to radiochemical reactions
being completed in less time than traditional approaches, to further decrease the
overall radiochemical processing times, new methods are required to decrease or
eliminate the time taken to process and activate the starting [18F]fluoride. One
option is to trap the [18F]fluoride onto a resin and subsequently perform on-resin
radiofluorinations, thus eliminating the need for azeotropic evaporations and
re-solubilization of the [18F]fluoride complex. Reusable polymer-supported
phosphazenes have been investigated as suitable resins to perform the [18F]fluoride
trapping and radiofluorination [26]. The PS-P2
tBu resin was able to trap >99% of
[18F]fluoride, with no leaching of activity was observed when the column was
subsequently dried with helium gas. It was found that substrates with sulfonate
leaving groups resulted in the highest RCY when subjected to on-column
radiofluorination. The same phosphazene resin could be recycled at least three
times using the same substrate, or at least two times using a different substrate,
which implies that the DOD production of radiotracers is possible through solid-
phase radiofluorination.
Other work in this area includes a continuous-flow system comprising a
polystyrene-imidazolium-chloride (PS-Im+Cl) monolith which traps [18F]fluoride
[27]. A solution of base and the relevant precursor could then be flowed through the
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PS-Im+[18F]F monolith into a preheated microfluidic chip where the radiochem-
ical reaction takes place. The advantage of this method is that the entire process is
performed in continuous flow and the microfluidic platform has a very small
footprint compared to current processes.
6.4.5 Droplet Systems
An interesting extension in the field of microfluidic radiochemistry is through the
use of droplets. Also sometimes referred to as segmented flow chemistry, it features
droplets (nL- μL) which are separated by an immiscible carrier fluid, similar to oil
droplets in water. Droplets can be thought of as individual nano- or microreactors
and can be used to aid radiolabeling optimization, whereby each droplet is the result
of a predetermined set of reaction parameters. Droplets consisting of approximately
120 nL were formed during the coupling of [18F]FSB with an anti-prostate stem cell
antigen diabody [28]. Using a 5 μL sample of the diabody solution was sufficient to
screen over 100 different reaction conditions using the droplets, and hence, the
optimal reaction conditions were determined rapidly with minimal use of the
precious diabody solution. Droplet systems have also been utilized in
electrowetting-on-dielectric (EWOD) devices. In EWOD systems, droplets are
sandwiched between two plates; the bottom plate consists of electrode pads to
manipulate the movement of the droplets throughout the microchip, while the top
plate electrically grounds the droplets. The EWOD chip was first used in the
synthesis of [18F]FDG [29], but its use has more recently expanded to include
[18F]FLT [30], [18F]fallypride [31], and [18F]SFB [32]. While the EWOD chip
produces these radiolabeled molecules in comparable, if not greater, RCY than
previously, drawbacks of the system include off-chip purification and the potential
for radioactivity and volatile side products to escape since the chip is exposed to air.
It is envisaged that with advances in technology, the EWOD chip could be further
automated, be disposable, and lead to scientists producing their desired radiotracer
on demand.
6.5 Challenges and Future of DOD
As it can be seen, a perfect DOD system is still not existent, but several data are
available demonstrating that such approach should represent the reality in the next
future. However, to witness this paradigmatic change, several challenges need to be
fronted, and they will represent the future of DOD research in radiopharmaceutical
production.
One of the biggest challenges is to understand whether one only system could
achieve the desired spread of operations that a DOD process should implement.
This should cover not only the production steps but also the switching of chemicals,
cleaning, and priming steps. It is very likely that these systems will be based on
86 G. Pascali and L. Matesic
micronized approaches (e.g., microfluidics, nanodroplets), but understanding which
philosophy they should implement is still under discussion. For example, a system
can be projected to implement several different preexisting routes, which would
lead to different products in different quantities, or, on the contrary, be represented
by a fixed framing to which flexibly interface single-use components/modules (i.e.,
similar to microcassettes) to build up the desired process. Another possibility might
also be represented by the possibility to use the exact same system into which
different chemicals are delivered, depending on the production needs. All these
options are amenable to deliver a DOD system, but the choice of one or the other
will drive the final performance and actual ease/flexibility of use.
Even once the underlying philosophy is clarified, some technical problems are
still unsolved or partially addressed. Purification of the finished product represents
probably the most important issue, and while there are several excellent systems to
perform chemical reactions, there is a notable lack in miniaturization of purification
methods or their interfacing with micronized chemistry systems. Some research is
now available on micro-chromatographic systems [33], mainly facilitated by the
advancements of monolith polymers [34] that can be easily integrated with micron-
sized channels/reservoirs [35]. These solutions allow the reduction of inherent void
volumes, therefore improving the atom efficiency in the purification process. Also,
similar solutions may be useful for the cases in which a simple solid-phase
extraction (SPE) would be sufficient to purify the relevant molecule [36, 37]. Poly-
mer chemistry advancement possibly represents the field where useful innovations
can have a relevant impact on miniaturized purifications. As an example, molecu-
larly imprinted polymers (MIP) represent a promising approach that would allow to
streamline the selective separation of the molecule of interest and its efficient
elution [38]. MIP structures are prepared by building the polymer pores around a
desired template molecule; once the template is removed, the material acquires
selectivity of shape and electronic interaction (i.e., with functional groups of
polymer) for the desired molecule [39]. MIP systems are in fact also referred as
“synthetic receptors.”
Another innovation that would be generally useful in radiochemistry but partic-
ularly applicable to DOD systems (due to their preferred micronized nature) is the
use of supported precursors. These systems should be projected in such a way that
the labeling reaction is the only event that would make the molecular structure to
become free from the solid support bond. In this way, no other complex organic
species will be present in the resulting mixture, and only simple filtration and
reformulation steps would be required in order to retrieve the radiopharmaceutical.
Some systems based on supported sulfonates [40] or triazene [41] have been
reported up to date, and patent literature also refers to examples of supported
ionic precursors (e.g., iodonium compounds) [42]. However, none of these systems
have demonstrated a preferential use compared to traditional methods, probably
because of the mismatch between the support active surface and reagent accessi-
bility to it. The use of micronized systems could be beneficial in solving this
mismatch, and indeed the use of sulfonate precursors supported on a monolith
structure grown directly in a microfluidic chip gave satisfying yields of
radiofluorination [43].
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A further modification to this approach, which would facilitate the respect of
DOD requirements, could be the use of reversibly linked precursors. In this concept,
the precursor should form a bond (e.g., covalent coordination) with the support
material, and as usual, the labeling reaction should be able to selectively cleave the
structure from the support; however, in a second “recycling” step, a change in
conditions will allow the recovery of the precursor out of the system and offer a
support free to be reversibly functionalized again with a different precursor. A
recent paper reported the catalysis by TiO2 nanoparticles in radiofluorinating a
tosylate precursor [44]; interestingly enough, the authors suspect that the process is
catalyzed due to selective coordination of the tosylate moiety with the titania
surface, therefore opening to the idea of a reversible functionalization of metal
nanoparticles with several different precursors prior to radiolabeling. Another
possibility, drawn from the field of self-healing materials, might be the use of
reversible click reactions, a nice example of which is represented by the 1,2,4-
triazoline-3,5-dione chemistry (TAD) moieties. This structure reacts in a reversible
way (using different temperatures, Fig. 6.2) with indoles through an ene click
reaction [45]; however, it undergoes fast Diels-Alder reactions with dienes and is
Fig. 6.2 TAD residue in reversible click-chemistry transformations (Taken from [45])
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widely used in biology for its capacity to bind irreversibly tyrosine residues
[46]. Such an approach could be very useful in DOD processes aimed at protein
labeling, for which radiolabeled prosthetic groups enabling click chemistry are now
widely employed [47].
Another important point to clarify is whether DOD systems should produce
product vials (as in the traditional approach), a syringe/cartridge dose, or even
directly deliver the radiopharmaceutical preparation into the vein of the subject (see
Fig. 6.3). Though currently unlikely, the possibility to overcome the concept of
product vial is very appealing on the base of flexibility, atom efficiency, and
procedure streamlining. Therefore, an outstanding challenge is represented by
modifying the regulators’ view [48, 49] on the requirements needed to prepare
injectable radiopharmaceuticals for human use, in order to allow easier and more
personalized modalities of dose delivery. One of the ways to achieve such result is
represented by the change in quality control (QC) paradigms; in fact, the traditional
way to produce a separate vial for QC [50] should be overtaken by the possibility of
realizing a DOD process whose precise control and monitoring would represent
itself a guarantee of good-quality end product.
Fig. 6.3 Idealized concept for a DOD system, used to inject directly in the patient the desired
radiopharmaceutical
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6.6 Conclusions
Miniaturization and optimization of the biochemical hardware involved have cre-
ated a substantial personalization of several medical practices. A typical example of
this trend that has improved the treatment of diabetic subjects is the current
possibility for any person to check their glucose levels using a straightforward
handheld system, instead of reaching the nearest hospital and performing a proper
blood examination. This level of simplicity, flexibility, and personalization is
currently lacking in the important field of radiopharmaceutical production. How-
ever, several studies are starting to demonstrate that new chemical technologies
(e.g., microfluidics, high-tech polymers) can represent useful tools to achieve what
we can define Dose-On-Demand systems. Several challenges are still to be faced
before reaching such a useful target in an efficient and affordable way; we however
think that the realization of this capability will be the main way to allow the use of
rare and disease dedicated tracers whose widespread utilization is currently hin-
dered [51] by the existing radiopharmaceutical production paradigms.
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